Literature DB >> 17676588

Parathyroid hormone-related protein varies with sex and androgen status in nonsmall cell lung cancer.

Philippe R Montgrain1, Rick Quintana, Yvette Rascon, Douglas W Burton, Leonard J Deftos, Andrea Casillas, Randolph H Hastings.   

Abstract

BACKGROUND: In nonsmall cell lung cancer, tumor parathyroid hormone-related protein (PTHrP) expression predicts longer survival in women but not in men. To explain the sex-dependent survival effect, the authors proposed that hormonal influences decrease PTHrP in men versus women, that PTHrP inhibits tumor growth, and that the effect is greater in women than in men. The objectives of this study were to compare lung carcinoma PTHrP expression and carcinoma growth in male and female mice and to determine whether gonadal steroids regulate PTHrP in lung cancer cells.
METHODS: Tumor PTHrP content was measured by immunoassay, and tumor burden was assessed with multiple measures in BEN squamous cell orthotopic lung carcinomas in athymic mice. In addition, lung adenocarcinoma PTHrP messenger RNA (mRNA) values determined by microarray analyses were compared between men and women. Cultured lung cancer cells were assayed for PTHrP after treatment with estradiol or R1881, a synthetic androgen.
RESULTS: Lung carcinomas contained approximately 3 times more PTHrP in female mice than in male mice. Similarly, levels of PTHrP mRNA were significantly greater in adenocarcinomas from patients who were women than from patients who were men. Male mice had greater tumor burden than female mice. Androgen treatment reduced PTHrP in 3 lung cancer lines. Estradiol had no effect. Testosterone treatment also reduced lung carcinoma PTHrP in female mice.
CONCLUSIONS: Lung carcinomas in females expressed more PTHrP than in males possibly because of negative regulation by androgens in males. Female mice with higher tumor PTHrP content had significantly less tumor burden than male mice, supporting the hypothesis that PTHrP inhibits tumor growth. (c) 2007 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17676588     DOI: 10.1002/cncr.22922

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Lung carcinoma progression and survival versus amino- and carboxyl-parathyroid hormone-related protein expression.

Authors:  Randolph H Hastings; Philippe R Montgrain; Rick A Quintana; Boris Chobrutskiy; Ashkhan Davani; Atsushi Miyanohara; Sepi Mahooti
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-25       Impact factor: 4.553

2.  Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice.

Authors:  Satoshi Sakaguchi; Hisatsugu Goto; Masaki Hanibuchi; Shinsaku Otsuka; Hirokazu Ogino; Soji Kakiuchi; Hisanori Uehara; Seiji Yano; Yasuhiko Nishioka; Saburo Sone
Journal:  Clin Exp Metastasis       Date:  2010-05-13       Impact factor: 5.150

3.  PTHrP inhibits BMP-6 expression through the PKA signaling pathway in breast cancer cells.

Authors:  Dong Mi; Ming Zhang; Ji-dong Yan; Jie Zhang; Xu Wang; Qing Wang; Shuang Yang; Tian-hui Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-18       Impact factor: 4.553

4.  Cell cycle actions of parathyroid hormone-related protein in non-small cell lung carcinoma.

Authors:  Randolph H Hastings; Philippe R Montgrain; Rick Quintana; Yvette Rascon; Leonard J Deftos; Erin Healy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-07-24       Impact factor: 5.464

Review 5.  Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow?

Authors:  Mary C Farach-Carson; Sue-Hwa Lin; Theresa Nalty; Robert L Satcher
Journal:  Front Oncol       Date:  2017-08-07       Impact factor: 6.244

6.  GAGE: generally applicable gene set enrichment for pathway analysis.

Authors:  Weijun Luo; Michael S Friedman; Kerby Shedden; Kurt D Hankenson; Peter J Woolf
Journal:  BMC Bioinformatics       Date:  2009-05-27       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.